{"meta":{"query_hash":"21bfcc07159b","filters":{"venue":"Clinical Lymphoma"},"cohort_total":7,"direct_labels_cover":0,"predictions_cover":7,"exported":7,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/21bfcc07159b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Lymphoma"},"results":[{"id":"W1974738398","doi":"10.3816/clm.2005.n.030","title":"A Randomized Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin as Salvage Chemotherapy Followed by Posttransplantation Rituximab Maintenance Therapy Versus Observation for Treatment of Aggressive B-Cell and T-Cell Non-Hodgkin's Lymphoma","year":2005,"lang":"en","type":"article","venue":"Clinical Lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Salvage therapy; Etoposide; Internal medicine; Oncology; Vincristine; Gemcitabine; Cytarabine; Carboplatin; Febrile neutropenia; Surgery; Chemotherapy; Rituximab; Neutropenia; Cyclophosphamide; Cisplatin; Lymphoma","score_opus":0.045795418080093964,"score_gpt":0.36480908885507635,"score_spread":0.3190136707749824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974738398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98725843,0.005663087,0.00025600867,0.0003467474,0.00023926499,0.005814325,0.0001885713,0.00004275375,0.00019079013],"genre_scores_gemma":[0.97391915,0.017696496,0.006919248,0.00020257557,0.000113635455,0.0006735006,0.00024268204,0.00007873736,0.00015399084],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959782,0.000354808,0.0017549082,0.0010077138,0.00044240963,0.00046196365],"domain_scores_gemma":[0.9905121,0.006696046,0.0016313929,0.00051796343,0.00030035854,0.000342178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087389944,0.00066921365,0.0025698668,0.00017216214,0.00015109021,0.00004360023,0.00012179869,0.00035184153,0.000020257607],"category_scores_gemma":[0.0004842803,0.0005121028,0.00042187155,0.00026282488,0.00046410988,0.00020919711,0.000030740477,0.000056075824,0.0000022448307],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63311845,0.030899199,0.018706135,0.00016159695,0.0014819037,0.00006063108,0.0022472877,0.000002720473,0.0062188455,0.00003846294,0.00020897757,0.30685577],"study_design_scores_gemma":[0.8992887,0.030609258,0.03963176,0.00018439208,0.0018506233,0.000024536397,0.0006165365,0.0028055855,0.024226306,0.000026760867,0.00032616168,0.0004093448],"about_ca_topic_score_codex":0.0005857235,"about_ca_topic_score_gemma":0.00007320231,"teacher_disagreement_score":0.30644643,"about_ca_system_score_codex":0.00021309206,"about_ca_system_score_gemma":0.00023545648,"threshold_uncertainty_score":0.99973303},"labels":[],"label_agreement":null},{"id":"W1983990351","doi":"10.3816/clm.2003.n.024","title":"Primary Adrenal Lymphoma","year":2003,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Incidence (geometry); Disease; Regimen; Adrenal insufficiency; Chemotherapy; Radiation therapy; Internal medicine; Oncology; Surgery","score_opus":0.12187550382528436,"score_gpt":0.420515326986854,"score_spread":0.2986398231615697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983990351","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009543734,0.95894223,0.000023321474,0.000047835354,0.0017342373,0.00097652467,0.00006755316,0.00019124457,0.03792164],"genre_scores_gemma":[0.000009134758,0.97456723,0.0005996117,0.002130537,0.0020139331,0.00009406756,0.00057827437,0.00017881756,0.019828368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99409074,0.00057794736,0.0027432346,0.0011966439,0.00061881955,0.00077261333],"domain_scores_gemma":[0.9956132,0.0011896446,0.00084155455,0.0012861347,0.0001397512,0.0009296943],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010482285,0.00090375537,0.0052997223,0.00023639265,0.00012460927,0.000039592356,0.0004705723,0.0013489248,0.00083670294],"category_scores_gemma":[0.0006231881,0.0006393799,0.0032200927,0.0006620373,0.00045823798,0.0000646705,0.00019618019,0.00047436438,0.0046639554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008535958,0.0008474043,0.000033375563,0.0077425903,0.0004375621,0.0062807375,0.00000404763,1.3076029e-8,4.8595963e-9,0.0002591499,0.018697694,0.96561205],"study_design_scores_gemma":[0.0029064019,0.00045409135,0.0010938931,0.011925654,0.0028016737,0.020817898,0.0000029034804,0.0000011452858,1.9340713e-7,0.00008119407,0.959275,0.0006399446],"about_ca_topic_score_codex":0.000006388863,"about_ca_topic_score_gemma":8.040259e-7,"teacher_disagreement_score":0.96497214,"about_ca_system_score_codex":0.00043479246,"about_ca_system_score_gemma":0.0036953704,"threshold_uncertainty_score":0.99994755},"labels":[],"label_agreement":null},{"id":"W1994225339","doi":"10.3816/clm.2003.n.019","title":"Lymphomas and Oncolytic Virus Therapy","year":2003,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"","keywords":"Oncolytic virus; Viral therapy; Virology; Lymphoma; Virus; Cancer therapy; Medicine; Cancer; Immunology; Coronavirus disease 2019 (COVID-19); Internal medicine; Disease; Infectious disease (medical specialty)","score_opus":0.11932318518071762,"score_gpt":0.44319979133702225,"score_spread":0.32387660615630465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994225339","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023952099,0.9947034,0.000007019428,0.000021675785,0.00046969685,0.00088229217,0.00006846971,0.00002805337,0.0014241872],"genre_scores_gemma":[0.000048437752,0.994365,0.00010182895,0.0007508772,0.0008429016,0.00016076017,0.00020904887,0.00017387832,0.0033472648],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954793,0.00115878,0.0011833258,0.0012511229,0.00030905643,0.00061842974],"domain_scores_gemma":[0.9974944,0.0002924624,0.00036668472,0.0013127401,0.00010107236,0.000432632],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013845513,0.00066218915,0.0017511791,0.00010959784,0.00013452522,0.00008272915,0.0006725256,0.001310757,0.00014115026],"category_scores_gemma":[0.0003215707,0.00047183534,0.00097057654,0.00024358016,0.000510198,0.0000034015266,0.0002598963,0.00024937544,0.0002614476],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039628922,0.00030081335,0.000015673842,0.000496604,0.0004059173,0.000026570135,0.0000025630295,5.1327426e-8,0.000049452676,0.000013504769,0.0031824727,0.9951101],"study_design_scores_gemma":[0.0019218381,0.0035757015,0.00002004907,0.00048695362,0.00013509816,0.000115963056,0.0000025425109,0.0000012834297,0.00018792214,0.000050190418,0.99291193,0.00059049367],"about_ca_topic_score_codex":0.00000782689,"about_ca_topic_score_gemma":0.000024952395,"teacher_disagreement_score":0.9945196,"about_ca_system_score_codex":0.000085364045,"about_ca_system_score_gemma":0.0015992104,"threshold_uncertainty_score":0.99998575},"labels":[],"label_agreement":null},{"id":"W2079316702","doi":"10.3816/clm.2005.n.010","title":"Potential Impact of a Single Nucleotide Polymorphism in the Hyaluronan Synthase 1 Gene in Waldenström's Macroglobulinemia","year":2005,"lang":"en","type":"article","venue":"Clinical Lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"RNA splicing; Single-nucleotide polymorphism; Hyaluronan synthase; Gene; Biology; Intron; Genetics; Molecular biology; Genotype; RNA","score_opus":0.03790136286088836,"score_gpt":0.37230771499822624,"score_spread":0.3344063521373379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079316702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562293,0.000604422,0.00001599005,0.001476176,0.00016463551,0.00062513683,0.000030237017,0.000032718814,0.0014277332],"genre_scores_gemma":[0.9972182,0.00010456531,0.0007952226,0.0007103652,0.00083899684,0.000021492006,0.00002969783,0.000047425874,0.00023404333],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959157,0.00041308027,0.0015432368,0.00057579303,0.00076146604,0.00079071906],"domain_scores_gemma":[0.99743795,0.0009301627,0.00022165186,0.0009933063,0.000101411155,0.00031550237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017785304,0.0002902326,0.00081657997,0.00024483952,0.00004069448,0.000029206656,0.0005542318,0.00033481052,0.00037172274],"category_scores_gemma":[0.0012840404,0.00019914634,0.00059909356,0.0006385216,0.00057325186,0.000104831524,0.00019886515,0.00037748643,0.00018365712],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078360075,0.013378085,0.0964465,0.00018141548,0.0003402472,0.010783103,0.0009067363,0.0006171024,0.02341021,0.00012218703,0.004655536,0.8413229],"study_design_scores_gemma":[0.084563114,0.004039716,0.8635104,0.0004896006,0.00018062713,0.0033778124,0.00022754053,0.03663098,0.0039709173,0.00019220586,0.0022880214,0.0005290935],"about_ca_topic_score_codex":0.0027966138,"about_ca_topic_score_gemma":0.00037267746,"teacher_disagreement_score":0.8407938,"about_ca_system_score_codex":0.0068561053,"about_ca_system_score_gemma":0.005176132,"threshold_uncertainty_score":0.9969564},"labels":[],"label_agreement":null},{"id":"W2090941758","doi":"10.3816/clm.2005.n.028","title":"ABVD, the Stanford V Regimen, and BEACOPP for Hodgkin's Lymphoma: What Should an Oncologist Do?","year":2005,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"ABVD; Medicine; Vincristine; Regimen; Vinblastine; Dacarbazine; Bleomycin; Prednisone; Etoposide; Internal medicine; Oncology; Hodgkin's lymphoma; Lymphoma; Chemotherapy; Cyclophosphamide","score_opus":0.2624196302931387,"score_gpt":0.49752479171567293,"score_spread":0.23510516142253424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090941758","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006815971,0.9891603,0.000017074844,0.0022037916,0.0015191075,0.0049444637,0.00026482766,0.00017239893,0.0010364121],"genre_scores_gemma":[0.0002742703,0.98669356,0.0012586953,0.0040698475,0.002979121,0.0018368617,0.000732544,0.0001981349,0.0019569374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935453,0.00054545543,0.002547664,0.0017820376,0.00062181795,0.00095774257],"domain_scores_gemma":[0.99037117,0.005310973,0.0011195547,0.0020944537,0.00025160267,0.0008522492],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021179114,0.0012013345,0.0046910034,0.0001686707,0.00042459794,0.00068220287,0.00069251045,0.0016709272,0.00007057711],"category_scores_gemma":[0.0008531851,0.0006761185,0.0020682584,0.0003350437,0.00096424593,0.00054675166,0.00033618175,0.00027380456,0.00011531453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031139728,0.0028486347,0.00018609472,0.002117384,0.0009969174,0.00021101239,0.000043323045,5.7857033e-8,1.9473358e-8,0.0012544441,0.016001865,0.97602886],"study_design_scores_gemma":[0.010141828,0.003189292,0.0017704669,0.007640158,0.0067007905,0.00070173776,0.00016785816,0.000011071689,8.724381e-7,0.00014960456,0.96883845,0.00068785145],"about_ca_topic_score_codex":0.00004293895,"about_ca_topic_score_gemma":0.000068892965,"teacher_disagreement_score":0.975341,"about_ca_system_score_codex":0.0012570691,"about_ca_system_score_gemma":0.002094342,"threshold_uncertainty_score":0.9996251},"labels":[],"label_agreement":null},{"id":"W2092788376","doi":"10.3816/clm.2002.s.006","title":"Acute and Long-Term Toxicities Associated with Gemtuzumab Ozogamicin (Mylotarg®) Therapy of Acute Myeloid Leukemia","year":2002,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Gemtuzumab ozogamicin; Myeloid leukemia; Calicheamicin; Medicine; Leukemia; Pharmacology; Oncology; Internal medicine; CD33; Biology; Stem cell","score_opus":0.07021262687105202,"score_gpt":0.36695139610792527,"score_spread":0.29673876923687326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092788376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.133934,0.8621321,0.0000048788893,0.000033785862,0.00031862158,0.0020166514,0.0004605383,0.00017597238,0.0009234978],"genre_scores_gemma":[0.0021549205,0.9894756,0.00019226366,0.0002726379,0.00038454126,0.00013313335,0.001030791,0.00027243028,0.0060836608],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940115,0.00048195285,0.0025604495,0.0013426262,0.00076569826,0.0008377286],"domain_scores_gemma":[0.99440134,0.0017121981,0.0017315343,0.001416167,0.00022087751,0.0005179049],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00054850476,0.0012590372,0.00659026,0.0002997285,0.00011906025,0.00004893789,0.0004970373,0.0015409802,0.00036784433],"category_scores_gemma":[0.00023904651,0.00085253885,0.0013624802,0.0005633746,0.0010109455,0.00012317054,0.0002283817,0.000728361,0.00010683116],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050609885,0.00078080466,0.003004184,0.0023395228,0.015701443,0.0015449409,0.000070500115,5.3234718e-8,0.0000023179123,0.000012955744,0.000754692,0.9752825],"study_design_scores_gemma":[0.11322604,0.02205307,0.10007585,0.13293909,0.07391068,0.007570526,0.000047292542,0.00008954991,0.00013723975,0.00005975518,0.5451201,0.004770799],"about_ca_topic_score_codex":0.00003404609,"about_ca_topic_score_gemma":0.00001835733,"teacher_disagreement_score":0.9705117,"about_ca_system_score_codex":0.0037924726,"about_ca_system_score_gemma":0.0031819625,"threshold_uncertainty_score":0.9997552},"labels":[],"label_agreement":null},{"id":"W2102070406","doi":"10.3816/clm.2005.n.002","title":"Origins of Waldenström's Macroglobulinemia: Does It Arise from an Unusual B-Cell Precursor?","year":2005,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Canada Research Chairs","keywords":"Immunoglobulin class switching; Somatic hypermutation; Waldenstrom macroglobulinemia; Immunoglobulin D; Macroglobulinemia; B cell; Biology; Immunoglobulin M; CD40; Cytidine deaminase; Monoclonal gammopathy of undetermined significance; Immunology; Molecular biology; Antibody; Monoclonal; Genetics; Monoclonal antibody; Immunoglobulin G; Multiple myeloma; Cytotoxic T cell; Lymphoma","score_opus":0.09611683324481807,"score_gpt":0.4676728339755265,"score_spread":0.37155600073070844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102070406","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011117951,0.98018426,0.00001661315,0.00018131184,0.0014887475,0.0021386961,0.0009928915,0.00019334546,0.0036861927],"genre_scores_gemma":[0.0009448976,0.98564905,0.0018953963,0.00041853578,0.005242692,0.00011978628,0.0013386317,0.00027373244,0.0041172695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900248,0.00087906123,0.004415204,0.0020231968,0.001479121,0.0011786197],"domain_scores_gemma":[0.98982686,0.0038190035,0.0014186051,0.0030414273,0.00042311757,0.0014709982],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014477392,0.0011462457,0.0064564366,0.0003233906,0.00009110642,0.00007180866,0.0014545816,0.0027805504,0.0011044355],"category_scores_gemma":[0.0015864997,0.00076339976,0.002472515,0.00068940216,0.0011053856,0.00015689054,0.00063863606,0.0013402053,0.0016606529],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00038528707,0.0027240345,0.00005164682,0.008053953,0.0006440518,0.0010895459,0.000057914818,4.501747e-7,7.887736e-7,0.00011240505,0.0040671686,0.98281276],"study_design_scores_gemma":[0.018618219,0.0009953203,0.00003884205,0.010383441,0.0037068257,0.00037974515,0.000045192308,0.00035635894,0.000035788315,0.000050088474,0.964662,0.00072816096],"about_ca_topic_score_codex":0.0015703252,"about_ca_topic_score_gemma":0.00021046968,"teacher_disagreement_score":0.9820846,"about_ca_system_score_codex":0.024745835,"about_ca_system_score_gemma":0.03633261,"threshold_uncertainty_score":0.99980867},"labels":[],"label_agreement":null}]}